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Repression of the lysogenic pR 
promoter in bacteriophage TP901-1 
through binding of a CI-MOR 
complex to a composite oM-OR 
operator
Margit pedersen1, Jesper tvenge neergaard2, Johan cassias2, Kim Krighaar Rasmussen3, 
Leila Lo Leggio  3, Kim Sneppen4, Karin Hammer2 & Mogens Kilstrup2 ✉
A functional genetic switch from the lactococcal bacteriophage TP901-1, deciding which of two 
divergently transcribing promoters becomes most active and allows this bi-stable decision to be 
inherited in future generations requires a DNA region of less than 1 kb. The fragment encodes two 
repressors, CI and MOR, transcribed from the PR and pL promoters respectively. CI can repress the 
transcription of the mor gene at three operator sites (oR, oL, and oD), leading to the immune state. 
Repression of the cI gene, leading to the lytic (anti-immune) state, requires interaction between CI 
and MOR by an unknown mechanism, but involving a CI:MOR complex. A consensus for putative MOR 
binding sites (oM sites), and a common topology of three oM sites adjacent to the oR motif was here 
identified in diverse phage switches that encode CI and MOR homologs, in a search for DNA sequences 
similar to the TP901-1 switch. The OR site and all putative oM sites are important for establishment 
of the anti-immune repression of PR, and a putative DNA binding motif in MOR is needed for 
establishment of the anti-immune state. Direct evidence for binding between CI and MOR is here shown 
by pull-down experiments, chemical crosslinking, and size exclusion chromatography. The results are 
consistent with two possible models for establishment of the anti-immune repression of cI expression at 
the pR promoter.
Genetic switches are used by temperate bacteriophages to decide between their two alternative life cycles fol-
lowing injection of their DNA into the host bacterium1; the lytic cycle where the phage multiplies and kills the 
bacterium at once or the lysogenic cycle where killing is suspended. In the lysogenic life cycle of most phages, the 
lytic functions are silenced by a CI repressor, which also renders the host cell immune to subsequent attacks by 
phages with homologous repressors (superinfection immunity).
Lactococcal bacteriophage TP901-1, belonging to the industrially important P335 family of phages, appears 
to have a simple decision switch mechanism2–5 involving two competing repressors CI and MOR (Modulator Of 
Repression). The genes for CI and MOR are divergently transcribed from two promoters (PR and PL, respectively) 
located back to back (see Fig. 1) in almost perfect symmetry around a central operator (OR) recognized by CI4,6. 
Overlapping the lytic mor (PL) promoter is a second CI operator (OL), and a third (OD) is located in the distal part 
of the mor gene. This overall operator topology appears to be shared among many lactococcal and streptococcal 
bacteriophage switches, despite the fact that the operator sequences do not follow the same consensus7. The CI 
monomer consists of an N-terminal DNA binding region8, a helical hook region which mediates dimerization9 
and a C-terminal helical region of unknown structure necessary for multimerization3. Upon binding of CI dimers 
to each of these operators in the lysogenic state of the TP901-1 switch, the PL promoter is almost fully repressed 
ensuring low concentrations of MOR and lytic proteins, while the PR promoter is only partially auto-repressed 
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Figure 1. Regions with homology to the TP901-1 switch region at the nucleotide level. The nucleotide sequence 
of the switch region from bacteriophage TP901-1 was used in a search for similar sequences using the PSI 
BLAST web server. (a) Physical outline of the switch. Three different domains in the CI repressor are indicated 
by colors: N-terminal domain encoding DNA binding site (blue box, aa 1 to 80); middle CT1-domain encoding 
a flexible linker and a putative hook domain for tight dimerization (black box, linker aa 81 to 89, hook domain 
aa 90 to 121); C-terminal domain encoding multimerization sites (green box, aa 122 to 180). The mor gene is 
shown in red. Promoters PL and PR are shown as arrows and black boxes symbolizing −10 and −35 regions. 
Operator sites are shown as blue divergent arrows. White boxes in lower panel indicate areas of homology to 
the TP901-1 switch region found in genomes of various types of phage and pro-phage. (b) Top panel shows 
the nucleotide sequence of the OR region. The two half sites of the OR operator recognized by the N-terminal 
domain of the CI repressor are shown in blue. Putative OM operators, numbered OM1, OM2, and OM3 from left to 
right, are shown in red. Promoter −10 and −35 motifs are underlined and marked, with the PL (lytic) promoter 
transcribing towards right and the PR promoter towards left. (b) bottom panel shows an alignment of all OR half 
sites and OM sites, with consensus sequences for each type.
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resulting in an optimal CI concentration10. In the lytic state of the switch, the PR promoter is more severely 
repressed by MOR dependent repression while the PL promoter is de-repressed. The apparent simplicity of the 
system is however deceiving as genetic analysis has revealed that the CI protein is required in collaboration with 
MOR for repression of its own promoter3, so the cI gene needs to be transcribed at a certain level in the lytic state 
of the switch. A helix-turn-helix (HTH) DNA binding domain has been identified in the mor open reading frame, 
but MOR is apparently unable to bind efficiently to DNA by itself3. A model for MOR dependent repression of 
the PR promoter has hypothesized that a complex between CI and MOR is formed in solution4,11 and that this 
CI:MOR complex binds to an OM operator site located downstream from the PR promoter preventing transcrip-
tion of the cI gene3. To explain the lack of repression of the PL promoter in the lytic state, binding of MOR to CI 
must prevent binding to the OR, OL, and OD operator sites. Thus according to the TP901-1 switch model, MOR 
functions as anti-repressor of CI while CI functions as co-repressor for MOR in the lytic state.
Anti-repressors against C repressors are fairly common in phage switches for use in the lytic induction 
of lysogenic pro-phages, such as the Ant protein in P2212 and the SOS-induced Tum anti-repressor in phage 
18613,14. Anti-repressors have also been detected in decision switches, as exemplified by the Coi anti-repressor 
protein in bacteriophage P115. An anti-repressor function of MOR in the TP901-1 decision switching is there-
fore not unprecedented. Co-repressor proteins have also been detected among decision switches as the Lxs 
CI-co-repressor in bacteriophage P116,17. The suggestion that CI should function as a co-repressor for MOR is 
therefore not exceptional, and would add an interesting twist to the P1 paradigm.
In the present report we provide evidence for the last part of the TP901-1 switch model, i.e., that CI is 
co-repressor for MOR in the lytic state. Repression of the lysogenic PR promoter is obtained by binding of a 
CI-MOR complex to a composite binding site including the OR operator and flanking OM binding sites. While 
linear multimeric repressor structures are known to be stabilized by binding to stretches of operators, as exempli-
fied by the Cox repressor in P218,19 and the Apl repressor in phage 18620, we believe that this is the first report of a 
repressor structure in which two competing repressors are collaborating in stabilization of a common repressing 
complex for the benefit of the one. We supply bioinformatic evidence that such composite operator structures are 
present in the switches of a large and diverse group of phages using CI/MOR homologues including phages of 
human pathogens.
Analysis of decision switching has been possible due to the use of our unique switch plasmids, such as 
pMAP503 that enables the easy quantification of decision switching frequencies by plating transformants with 
the transcriptional fusion plasmids directly on agar plates containing X-gal. Switch plasmids also have the benefit 
in comparison with complete phage models that both the lysogenic (immune) state and the lytic (anti-immune) 
state are viable and may be subsequently analyzed3.
Results and discussion
A homologue of the entire switch module from bacteriophage TP901-1 was previously detected in prophage 
bIL285 in the Lactococcus lactis subspecies lactis laboratory strain IL140321. In the Lactococcus lactis laboratory 
strains MG136322 belonging to subspecies cremoris we have likewise found a small region corresponding the 
C-terminal domain of the CI repressor in the T712 prophage of MG1363 (data not shown). Since homologues of 
the TP901-1 switch exist even in the two most widely used laboratory strains it became interesting to do a BLAST 
search23 in the entire NCBI nucleotide collection for phages and pro-phages using closely related switch regions. 
A selection of very informative sequences (see Fig. 1) resulted from such a search for DNA regions with extensive 
similarity to the functional switch region present in switch plasmid pMAP50. All sequences corresponded to 
genomes of phages or pro-phages with Lactococcus, Streptococcus, Enterococcus, or Staphylococcus hosts.
A number of Lactococcus phages and pro-phages contained entire switch regions with extensive homology 
throughout the switch region and must be expected to use identical mechanisms in their decision switching as 
TP901-1 (e.g., pro-phages in L. lactis strains A76 (subsp. cremoris), A12, UC77, IL1403, 229 (all subsp. lactis), and 
phage bIL285). Of more interest, however, was the identification of a large number of streptococcal, staphylococ-
cal, and enterococcal phages and pro-phages that showed homology to the mor gene and the intergenic region, 
but only to the first part of the cI gene encoding the N-terminal domain, known to contain DNA binding domain. 
Beyond the N-terminal domain no similarity was detected to the TP901-1 cI gene for these phages (see Fig. 1a).
When the non-homologous C-terminals of these CI repressors were analyzed for known protein motifs, 
they were found to encode domains with high homology to more classic CI repressors24, which perform RecA 
dependent auto cleavage. Curiously, it has been shown that the CI repressor from TP901-1 does not seem to 
auto-cleave25, and no peptidase domain can be detected in the primary sequence.
A composite oM1-OM2-OR-OM3 operator complex is preserved in homologous phage 
switches. Since the DNA binding region of the CI repressor is located in the N-terminal domain of the 
phages and pro-phages identified above, the possibility remained that the homologous intergenic regions could 
reveal similarities relating to CI and MOR operator sites. Therefore, we did a manual curation of the intergenic 
regions from switches where homology spans the mor gene, the intergenic region, and the first part of the cI 
gene encoding the N-terminal domain. In this process a central CI operator sequence, corresponding to the OR 
site from TP901-1 (see Fig. 1b), was identified in the intergenic regions from Staphylococcus, Streptococcus and 
Enterococcus switches. All regions contain putative PL and PR promoters, following the normal promoter geometry 
and fitting the −10 and −35 consensus sequences perfectly. Previously we had considered the A-rich sequences 
flanking the OR sites as possible MOR binding sites, and the comparison in Fig. 2 shows that a [TCAACAnAA] 
or [TCAAnAAAA] motif is situated adjacent to the 5′-end of each OR half site in all the CI-MOR switches, with 
a spacing of one A nucleotide. Furthermore an extra motif [TGAACAAAA] is present on the PR-proximal site, 
spaced by two nucleotides (GT or AT).
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If the motifs (shown in red in Fig. 1b) serve as binding sites for MOR binding in the CI-MOR anti-immune 
complex, then the most straight forward binding mode (Model I in Fig. 2a) would be a MOR-MOR-CI2-MOR 
complex that binds linearly to the OM1-OM2-OR-OM3 operator complex and result in asymmetrical repression of 
the PL and PR promoters. Repression would be most severe for PR, as MOR-MOR binding to the OM1-OM2 opera-
tors might compete efficiently with RNA polymerase binding to this promoter. This model, however, has the twist 
that prevention of CI2 binding to the OL and OD operators will require a conformational change that prevents 
binding to OL and OD upon binding of MOR outside of the CI2 dimer, but which still allows CI2 binding to OR.
A second possibility which addresses this issue could be proposed in which the MOR protein binds to the 
CI2 dimer in a way that prevents normal CI2 binding to its operators (Model II in Fig. 2a). This geometry would 
have the benefit that it forces the two DNA-binding motifs on CI2 far apart, and prevent binding to OL, OD, or OR. 
However, the prevention of CI2 binding in Model II sacrifices the simplicity of binding to the composite operator. 
Figure 2. Models for binding of CI2-Mor complexes to a composite OM1-OM2-OR-OM3 operator, and functional 
domains in CI and MOR proteins. (a) In the absence of MOR, CI2 binds in its native conformation to the 
OR site. Sufficient concentrations of CI and MOR result in MOR:CI2 binding that lowers the affinity of Cl2 
towards OL, OD, and OR. Model I) MOR binds on the outside of CI2 which has the advantage that it enables a 
straight forward binding of a MOR-MOR-CI2-MOR complex to the composite OM1-OM2-OR-OM3 operator, 
but the drawback that prevention of CI2 binding to OL, OD, or OR is dubious. Model II) MOR binds on the 
inside of the “legs” of the CI dimer, which has the advantage that it prevent CI2 binding to OL, OD, and OR. 
This model however has the drawback that it requires binding between a MOR-MOR-MOR-CI2 complex 
and a composite OM1-OM2-OR operator. Binding of the protein complexes to the composite OM1-OM2-OR-OM3 
operator is stabilized by a number of protein:DNA and protein:protein interactions, each supplying binding 
energies, as represented by numbered arrows in the left panels. b,c) LOGO plots was created using the http://
weblogo.berkeley.edu/logo.cgi web based service, using an alignment of CI N-terminal Domain (b) or MOR 
(c) sequences from bacteriophages containing Switch regions with homology to the TP901-1 OR region and 
OM1-OM2-OR-OM3 topology (shown in Fig. 1). (b) Above the LOGO plot sequence the residues involved in 
CI-DNA binding is shown with arrows, as well as the location of a conservative R57K substitution previously 
identified to give a clear plaque phenotype. (c) Above the LOGO plot sequence the invariant K36 (MOR 
numbering) and variant D39 are shown as arrows. Most of the DNA binding HTH domain is conserved, with 
an α3 recognition helix motif ERxxSLK (E30 to K36), a turn motif, xLS (G27 to S29), and a stabilizing α2 helix 
domain QxNFxxAM (Q19 to M26). Aside from this an N-terminal α1 helix motif SxLxGxIxEK (S6 to K15) and 
a conserved central α4 helix motif DxEIxxAxxxL (D45 to L65) is shown.
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If Model II is right this will require that the CI-proximal MOR is stabilized by binding to the left OR half-site (ORL, 
see also Fig. 2a), which should then function as a pseudo-OM site, resulting in binding of a MOR-MOR-MOR-CI2 
complex to the OM1-OM2-ORL-ORR operator.
Model I and Model II have their pros and cons, and each rely on the importance of the OM sites identified by 
the phylogenetic analysis, and that these actually serve as MOR binding sites. To distinguish between the two 
models we will need to acquire much more information about the detailed interaction of MOR and CI. However, 
in support of either model, we will supply experimental in vivo evidence for the importance of the OR, OM1, OM2, 
and OM3 sites for the anti-immune repression of the PR promoter, as well as in vitro evidence of the CI-MOR, and 
MOR:MOR interactions that are functional prerequisites for all three models.
Mutation of the OR site decrease anti-immune repression of the PR promoter. For quantifica-
tion of the importance of the OR operator in the anti-immune repression of PR, the anti-immune state had to 
be secured in the L. lactis laboratory strain MG136322. Technically we needed to establish conditions where the 
PL promoter had won the “decision race” and resulted in sufficient levels of both CI2 and MOR to form the 
putative CI:MOR complex for binding to the OM1-OM2-OR-OM3 operator and secure repression of the PR pro-
moter. Plasmid pAB2232 contains the full switch region from TP901-1 carried on the low-copy number plasmid 
pCI334026 and is capable of establishing either the anti-immune phenotype described above, or the immune 
state where CI dimers in the absence of MOR bind to the OL, OR, and OD operators and repress the PL promoter2. 
Transformation of MG1363 derivatives with pAB223 has previously been shown to produce approximately 94% 
transformants in the anti-immune state with repressed PR levels, and 6% in the immune state with unrepressed PR 
levels2. Since strains carrying “switch plasmids” are phenotypically stable with respect to the switching state, we 
analyzed only a small number of MG1363/pAB223 transformants. Candidate MG1363/pAB223 transformants 
were subsequently transformed with the PR-lacLM fusion plasmid pJT2 (see Table 1). Plasmid pJT2 is based 
upon the integrative fusion plasmid pLB8627 and contains the intergenic region between the cI and mor genes 
from TP901-1 inserted upstream from the lacLM reporter genes. It includes both promoters and the OR and 
OL operators, but no functional phage genes. One positive transformant with severely repressed PR levels was 
selected and named JT2. The expression of β-galactosidase from this plasmid was approximately 40-fold elevated 
in the absence of pAB223 (see below), showing that the JT2 switch phenotype was indeed repressing for the PR 
promoter.
As mentioned above the binding of CI2 to the OR operator is important for the anti-immune repression of 
PR in either model. Therefore we constructed a mutant plasmid pJT3 where the right OR half site (ORR) was 
changed from [AGTTCACG] to [AGGATCCG] and creating a BamHI restriction site, identical to a published 
OR mutation3. pJT2 and pJT3 were integrated as single copy fusions into the chromosomal attB site in JT2 
(MG1363/pAB223 [anti-immune]) as well as in LB504 (MG1363/pLB65 [no CI or MOR present]). The average 
β-galactosidase levels, measured in biological triplicates, are shown in Table 1. It is clear that the mutation of the 
OR site severely reduces the anti-immune repression of the PR promoter, suggesting that the ORR site is important 
for the anti-immune repression. This conclusion appears to be in direct contradiction with a previous report3, 
where the exact same mutation was shown not to prevent anti-immune PR repression when it was present in the 
switch plasmid. Without going into a detailed discussion, the apparent contradiction may be explained by a 7-fold 
elevated MOR expression in the OR mutant under anti-immune conditions that could increase the formation of 
the CI:MOR complex and the extent of PR repression.
Fusion plasmid {genetic elements present} Mutation
β-galactosidase activity (differential synthesis 
rates)
PR level in JT2 
(SD)
PR level in 
LB504 (SD)
Repression 
fold
pJT2 lacLM {←PR OM1 OM2 ORL ORR OM3 PL →OL} None 0.17 (0.086) 6.6 (4.2) 40
pJT3 lacLM{←PR OM1 OM2 ORL [mut] OM3 PL→OL}
OR:
From AGTTCACG
To AGGATCCG
0.45 (0.53) 1.8 (1.7) 4
pJT5 lacLM{←PR OM1 OM2 OR OM3} None 0.20 (0.069) 4.3 (3.4) 20
pJT13 lacLM{←PR [mut] OM2 OR OM3}
OM1:
From TGAACAAAA-GT
To TGAACTCCA-GT
3.6 (0.31) 5.9 (0.097) 2
pMK1216 lacLM{←PR OM1 [mut] OR OM3}
OM2:
From TCAACAAAA-A
To TCAACCGTG-A
0.37 (0.072) 2.8 (0.52) 8
pMK1217 lacLM{←PR OM1 OM2 OR [mut]}
OM3:
From TCAACAAAA-A
To TCAACAAGT-T
0.82 (0.23) 2.1 (0.48) 3
pJT6 lacLM{←PR OM1 OM2 OR} OM3 deletion 0.46 (0.24) 1.3 (0.91) 3
Table 1. Importance of the OR operator for anti-immune repression of the PR promoter in the TP901-1 
switch. Expression levels from PR-lacLM reporter fusions in switch background (JT2) compared to a genetic 
background without CI and MOR (LB504).
6Scientific RepoRtS |         (2020) 10:8659  | https://doi.org/10.1038/s41598-020-65493-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
Mutation of the OM1, oM2, and oM3 sites decrease anti-immune repression of the PR promoter. 
After pointing at the importance of the ORR half site for the anti-immune repression of PR, the involvement of the 
putative OM1, OM2, and OM3 sites was tested using a library of random PCR generated mutations for each OM site 
targeting the A-rich areas. A selection of such mutants were measured as single copy fusions integrated into the 
chromosomes of JT2 and LB504, three of which (pJT13, pMK1216, and pMK1217) are shown in Table 1. To avoid 
interference with the OL operator and the PL promoter, a fusion plasmid pJT5 devoid of these elements was used 
for comparison between mutated and wildtype OM-sites. Plasmid pJT5 showed 20-fold repression and similar 
expression levels as pJT2 under both anti-immune and unrepressed conditions, showing that the interference 
between the two promoters can be neglected.
It is clear from the results in Table 1 that mutations in each of the three putative OM operators diminish the 
anti-immune repression of the PR promoter. It appears as if the OM2 site (with four consecutive mutated bases) is 
less crucial for full repression compared to OM1 and OM3 (with three and two mutated bases, respectively), which 
could reflect the increased stabilization of a MOR protein that is sandwiched between two MOR proteins (Model 
II) or between MOR and CI (Model I). Deletion of the entire OM3 operator (pJT6 in Table 1) has a similar effect 
as mutating the A-rich region (compared with pMK1217). Collectively, these data confirm our phylogenetic evi-
dence about the importance of the putative OM sites for establisment of anti-immune repression, presumably as 
operators for the CI:MOR anti-immune complex formation.
Due to an unusual and interesting response of the PR promoter to the optical density of the culture (see sup-
plementary material) we had to restrict our sampling to cell densities with OD450 values in the range between 0.25 
and 0.75 to get the best determinations. When quantifying PR repression in Table 1 the β-galactosidase activity 
was measured as the differential synthesis rate from three sample points within the restricted OD values and 
calculated as Δ(total enzyme activity)/Δ(OD450). It is highly interesting that the PR promoter shows this cell 
density or growth phase dependence, which resembles a quorum sensing response except for the low magnitude 
of the induction, but so far our analysis has not shed light on the mechanisms behind the dependence.
A DNA binding domain in the MOR protein is important for establishment of the anti-immune 
state. Above we showed that disrupting ORR, OM1, OM2, or OM3 had severe implications for establishment of a 
strongly repressing anti-immune complex, which we take as evidence for the importance of CI binding to the ORR 
half site and MOR binding to the three OM operators. In the following, we analyze the importance of a putative 
DNA binding site in the MOR protein for the establishment of the anti-immune state.
Previously a HTH domain between residues Q19 and N38, with close resemblance to DNA binding domains 
(see α2 and α3 in Fig. 2c) has been reported in the primary sequence of the MOR protein2. To analyze whether 
this putative DNA binding domain is important for the establishment of the anti-immune state, a conserved K36 
residue of the recognition helix was changed to an alanine along with a D39A substitution. To analyze the impor-
tance of the K36 and D39 residues in the MOR protein, we compared the switching frequencies of two switch 
plasmids, one with a wild type mor gene (pAB223) and one with a mutated mor gene producing the MOR K36A 
D39A variant (pMAP109). Because the two switch plasmids did not contain reporter genes, the switch status was 
monitored with a PL-lacLM promoter fusion present in the recipient strain (AJ189). When plasmid pMAP109 
was used to transform AJ189, and transformants were selected on solid media containing erythromycin and 
X-gal, only white transformants were obtained (data not shown), while transformation with pAB223 resulted in 
the expected 90 to 95% blue (anti-immune) colonies, showing that the putative DNA binding domain in MOR is 
important for establishment of the anti-immune complex.
Evidence for CI:MOR interaction by pull down experiments. Interactions between CI and MOR, 
which are crucial for both model I and II was analyzed by a simple pull-down experiment where we took advan-
tage of the strong salt sensitive unspecific DNA binding of CI, previously used in the purification of the native CI 
repressor28. When CI is expressed from an expression plasmid in E. coli strain AJ159, the entire pool of CI protein 
becomes bound to the chromosomal DNA after cell disruption (see Fig. 3a, lane 1), and is subsequently pulled 
down during centrifugation (Fig. 3a, lane 2). Suspension of the pellet containing DNA and CI in a 1 M NaCl 
solution results in elution of almost pure CI (Fig. 3a, lane 3). The DNA binding ability of CI was well known, but 
it was interesting whether the DNA binding motif on MOR, that was found to be important for establishment 
of the anti-immune CI:MOR repression (see above), could bind DNA so strongly that the MOR protein would 
precipitate with E. coli DNA. Expression of MOR protein on its own (i.e. in the absence of CI) from an expression 
plasmid in E. coli AJ172 (Fig. 3b, lane 1) was shown to result in a high MOR concentration only in the supernatant 
(Fig. 3b, lane 2), yet not in the DNA pellet following centrifugation (Fig. 3b, lane 3). In contrast, pull-down of 
MOR by binding to DNA-bound CI was in contrast very efficient. When an extract of AJ159 cells containing high 
concentrations of expressed CI protein was mixed with an extract of AJ172 cells containing high concentrations 
of expressed MOR protein (Fig. 3c, lane 1), both CI and MOR ended up in the pellet after cell disruption and 
centrifugation (Fig. 3c, lanes 2 and 3). This shows that MOR is pulled down from solution by the DNA-bound CI 
protein.
Interestingly, pull-down experiments using extracts of CI-overexpressing AJ159 cells mixed with extracts 
from MP1047 cells overexpressing a MOR[K36A D39A] recombinant protein also result in efficient pelleting 
of both proteins (data not shown). This shows that the CI-MOR interaction does not require that MOR has a 
native DNA binding domain, and must dependent upon strong CI-MOR binding that does not interfere with CI 
unspecific DNA binding.
A similar result was found when a heparin column was used to monitor binding of CI and MOR from cellular 
extracts (see Fig. 3d). Heparin is a polymer with a negative charge distribution that mimics the DNA backbone 
and is used in affinity chromatography to select for DNA binding proteins. CI was bound efficiently on the hep-
arin column (Fig. 3d, lane 1). In contrast all MOR protein could only be found in the run-through when it was 
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loaded on a pure heparin column (Fig. 3d, lane 2). However, if the column had been allowed to interact with puri-
fied CI, forming a complex between heparin and the CI DNA binding domain before addition of MOR extract, 
no MOR could be found in the run-through (Fig. 3d, lane 3). When CI binding to heparin was disrupted with 1 M 
NaCl, both CI and MOR was found in fraction 3 to 5 (Fig. 3d, lanes 6 to 8). This again confirms that the intrinsic 
DNA binding of MOR is too weak for affinity purification, but that CI:MOR interactions are strong enough to 
permit retention of a CI:MOR complex when CI is bound to DNA or heparin.
Evidence for CI-NTD:MOR interaction by gel filtration. Guided by the pull-down experiments above, 
we attempted to purify the complex by gel filtration after mixing purified full length CI and MOR. However this 
could not be achieved reproducibly. Instead, we attempted a number of binding experiments trying to pull-down 
various truncated constructs of CI with GST-tagged MOR as bait. Some CI constructs seemed to be retained fairly 
consistently on affinity columns where GST-tagged MOR was bound, and co-eluted with MOR upon glutathione 
addition. Similarly, tagged MOR was sometimes retained and co-eluted with His-tagged CI constructs on IMAC 
columns. Unfortunately the results were not always consistent (data not shown) so we went on to investigate 
Figure 3. Pull-down experiment using unspecific CI binding to chromosomal DNA or heparin. E. coli cells 
expressing CI (AJ159, a and c) or MOR (AJ172, b and c) were disrupted by sonication, either separately (a,b) 
or together (c), and centrifuged. Samples were withdrawn after sonication (lane 1), from the supernatant after 
centrifugation (lane 2), and from the pellet after elution of CI with 1 M NaCl (lane 3). Proteins were solubilized 
in SDS buffer and separated by SDS PAGE, followed by coomassie staining. Lanes marked M contained protein 
weight standards with molecular weights as shown left of each band. (d) CI and MOR extracts were prepared 
from overexpressing E. coli cells (AJ159 and AJ172, respectively) after sonication and centrifugation. MOR 
protein extracts were sampled from the supernatant after centrifugation, while CI extracts were obtained by 
elution of CI from the centrifugation pellet in 1 M NaCl. Lane 1) Binding of CI extract to a heparin column 
(CI:heparin) followed by elution with 1 M NaCl. Lane 2) Run-through from binding of a MOR extract on a 
heparin column. Lane 3) Run-through from binding of a MOR extract to a CI:heparin column. Lanes 4 to 9) 
Elution of bound CI and MOR from a CI:heparin column with 1 M NaCl, in small fractions. Proteins were 
solubilized in SDS buffer and separated by SDS PAGE, followed by coomassie staining. Lanes marked M 
contained protein weight standards.
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whether some of the available His-tagged CI constructs of different length could form complexes with MOR 
that were stable enough to be detected in gel filtration experiments. Accordingly, a construct of CI (CI-NTD1–89) 
including the N-terminal domain and the flexible linker, clearly formed a stable complex with MOR in gel filtra-
tion experiments (Fig. 4). After purification of GST-MOR by affinity chromatography, the GST linker had been 
cleaved off and MOR was further purified.
When the CI and MOR proteins were analyzed separately (Fig. 4), they migrated with molecular weights 
close to the expected 11 kDa for the CI-NTD89-His6 monomer (blue curve, 13 kDa estimated), and 8.4 kDa 
for the MOR monomer (red curve, 11 kDa estimated). It thus appears that they were both in the monomeric 
state at the concentrations used (38 μM and 10 μM, for CI-NTD89-His6 and MOR respectively). A mixture of 
CI-NTD89-His6 and MOR-His6 in 4:1 molar ratio (orange curve in Fig. 4), resulted in disappearance of the peak 
for MOR as expected and appearance of a peak with an estimated size around 15 kDa, which we interpret as a 1:1 
complex of CI and MOR. The relative areas of the two peaks (the larger containing CI and the smaller containing 
CI and MOR) were estimated to be 1:3.9 in accordance with the expectation that a large fraction of MOR-His6 
monomers had combined with CI-NTD89-His6 to form CI:MOR hetero-dimer complexes. There can be a num-
ber of explanations why our experiments with larger constructs of CI failed to show stable complexes with MOR 
under gel filtration conditions, and possibly our success with the CI-NTD89 protein could be due to the fact that 
its mobility rate is close to that of MOR and prevent separation of the two proteins during elution. At any rate, 
we interpret this experiment as definite in vitro proof of formation of a CI-NTD: MOR complex in the absence of 
DNA. Comparison of CI proteins from phages with and without MOR proteins previously identified a domain in 
the NTD region that was conserved only in CI repressors with MOR partners, and was suggested to contain the 
MOR interaction site25, but to our knowledge this is the first demonstration of a CI:MOR complex at the protein 
level.
Evidence for CI:MOR and MOR:MOR interaction at high concentrations by chemical 
cross-linking in vitro. To verify that also full length CI and MOR form a stable complex we attempted to 
cross-link the proteins chemically. To prevent cross-linking of the protein impurities, pooled fractions from gel 
filtration of the individual (untagged) proteins were used. Detection of specific cross-linked CI:MOR complexes 
did not prove to be easy, as we could not with certainty detect bands of the correct size after SDS PAGE analysis of 
the linked products (see Fig. 5c,d). Instead CI:MOR binding was shown indirectly by first detecting MOR-MOR 
adducts when MOR protein was cross-linked alone, and then showing that these adducts were converted to 
higher molecular weight adducts when CI was added together with MOR (see Fig. 5a,c,d). The formation of 
MOR:MOR (MOR2) complexes is a prerequisite for both model I and model II for the anti-immune CI:MOR 
complex, so the detection of a cross-linked MOR-MOR dimer complex is consistent with either model.
In the in vitro cross-linking assay where high concentrations of MOR at 20 μM and low salt concentration 
(100 mM) were used to compensate for a low binding affinity, cross-linked MOR:MOR adducts could be detected 
already after 2 minutes of incubation with glutaraldehyde (Fig. 5a, lane 2). The level of the cross-linked dimer 
species remained constant during the 60 min of incubation (lane 6). Larger cross-linked MOR adducts could be 
detected after 10 min of cross-linking (lane 4 to 6), but at a much lower level.
When purified CI protein at 20 mM was cross-linked in the absence of MOR, many different types of 
cross-linked CI-adducts could be detected (Fig. 5b). This was expected because in addition to the stable dimer 
conformation the CI protein is known to form larger oligomers such as hexamers in solution3. The dominant 
species appears to be a cross-linked CI-dimer in Fig. 5b, whose level decrease slightly between 2 min and 60 min 
cross-linking. In the presence of equimolar concentration of MOR (20 μM), the band corresponding to the CI2 
adduct vanishes more rapidly with time (Fig. 5c), most likely due to the formation of larger cross-linked CI2-MOR 
adducts. No clear bands corresponding to such adducts are present in the separation gel, but a dense smear 
accumulate in the stacking gel above the separation gel at time points after 5 minutes of crosslinking, indicating 
Figure 4. Comparison of free and bound CI-NTD89 and MOR. CI-NTD89 (blue), MOR (red), and a ~4:1 
mixture of CI-NTD89:MOR (yellow) were purified using SEC SuperDex75 Prepgrad column. Normalized 
elution profiles were compared to verify complex formation. The two proteins, CI-NTD89 and MOR eluted as 
a single peak at 226.47 mL and 234.12 mL, respectively. In contrast the mixture (CI-NTD89:MOR) elute as two 
peaks at 219.10 mL and 228.04 mL, corresponding to Mw = 15.1 kDa and 12.8 kDa.
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the presence of large non-uniform crosslinked structures. Under these conditions, MOR protein appears to be 
in surplus resulting in the detection of MOR monomer and cross-linked MOR-MOR adducts. When the level 
of MOR is lowered to 4 μM (Fig. 5d), it becomes clear that bands corresponding to both MOR monomer, the 
MOR-MOR adduct, and the CI2 adduct all vanishes from 2 min to 60 min cross-linking. When the level the CI2 
adduct is compared between Fig. 5c,d, it is clear that the MOR protein is responsible for the disappearance, most 
likely through a MOR:CI2 or MOR2:CI2 complex formation.
All and all the cross-linking experiments in Fig. 5 support both models I and II in directly detecting 
MOR:MOR interactions and indirectly showing CI:MOR interactions.
A CI interaction domain on MOR. CI:MOR interactions require both a MOR interaction domain on 
CI and a CI interaction domain on MOR. We have demonstrated above previous suggestions that N-terminal 
domain of CI contains the MOR binding site. It has also been established by introduction of stop codons in the 
mor reading frame3 that a full size MOR protein is needed for bistability of switch plasmids, since 100% white 
transformants (in the immune state) were obtained when the nonsense mutants were introduced into TP901-1 
switch plasmids. A stop codon at position 63 in the mor reading frame will result in a truncated MOR protein 
devoid of the last 10 amino acids including a conserved YF motif in the last (α5) helix which can be identified 
in the alignment of MOR proteins from the MOR-encoding phages harboring the OM1-OM2-OR-OM3 operator 
(Fig. 4b). The inability of this truncated MOR protein to engage in bistability suggests that the YF motif or possi-
bly all of helix 5 is important for stability of the anti-immune operator complex.
Two conceptual models for TP901-1 bi-stability in decision switching. Above we have reported a 
number of experiments where the results appeared to support both models. To make it easier to see if any of the 
experiments could offer conclusions that point at one model over the other, we have outlined the possible stable 
endpoints of the decision process for the two contrasting models in Fig. 6(c,d). Three protein domains are high-
lighted for the CI protein, the DNA and MOR binding N-terminal domain in blue, the hook forming dimerization 
domain in black, and the multimerization domain in green. It is not clear whether the multimerization domain 
function as a secondary low affinity dimerization domain promoting ring-formation into hexamers or higher 
multimers (as suggested in Fig. 6b), or whether the C-terminal forms hexamers with a more complex interaction 
domain. Compared to a previous model25 we have introduced the OM sites and specified how an anti-immune 
repressing complex may be bound to the composite OM1-OM2-ORL- ORR-OM3 site in the anti-immune state.
Figure 5. Identification of CI:CI, MOR:MOR, and CI:MOR interactions by chemical cross-linking in vitro 
Interacting proteins were chemical cross-linked with glutaraldehyde for 0, 2, 5, 10, 30, and 60 minutes (lanes 1 
to 6). Purified protein in the cross-linking experiments was MOR alone (purified from AJ172) at 20 μM (a), CI 
alone (purified from AJ159) at 20 μM (b), MOR at 20 μM and CI at 20 μM (c), or MOR at 4 μM and CI at 20 μM 
(d). The cross linked samples were separated by SDS PAGE and coomassie stained.
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As explained previously, Model I presupposes that MOR binds to a part of the N-terminal domain which faces 
outward if the CI2 dimer is bound to the OR operator. Model II presupposes that the binding is on the opposite 
side of the N-terminal domain.
Figure 6a shows the geometry of the minimal switch region, which is able to perform decision switching, and 
6b shows the outcome of the immune switching phenotype, common to all three models. CI monomers expressed 
from the cI gene dimerize and bind to OR, OL, and OD, either before or after hexamer formation.
Logically, model I (Fig. 6c) is the most straight-forward consequence of the switch geometry, because it would 
enable CI2 to bind to OR both under immune and anti-immune conditions. As a MOR:CI2:MOR complex the 
cI gene
mor gene
PL
PR
a
b cI gene
mor gene
PL
PR
OR OL OD
cI gene
mor gene
PL
PR
OM1-OM2-OR-OM3 
d
cI gene
mor gene
PL
PR
OM1-OM2-OR-OM3 
c
Figure 6. Two models for TP901-1 decision switching. (a) Physical map of the switch region. Genes are shown 
as colored boxes and labeled; promoter −10 and −35 elements are shown as black boxes; Binding sites are 
shown as colored arrows. Promoters and mRNA is shown as labeled black lines and arrows. (b) The immune 
state. CI repressor is shown with three domains: the NTD (DNA binding and MOR binding, blue); the CTD1 
(dimerization hook domain black); and the CTD2 (multimerization domain, green). Between the NTD and the 
CTD1 a flexible linker ensures high freedom of the DNA binding angle in the CI2 dimer. (c) The anti-immune 
state according to Model I. MOR protein is shown as a single red domain, with the ability to bind DNA (OM 
sites, red), to bind the CI-NTD domain and to form MOR:MOR dimers. (d) The anti-immune state according 
to Model II. MOR protein is shown as a single red domain, with the ability to bind DNA (ORL and OM sites, red) 
to bind the CI-NTD domain, and to form MOR:MOR dimers.
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central CI2 would bind to the central OR site in the composite OM2-OR-OM3 operator site with a lowered affinity 
which is then compensated by the binding of the flanking MOR molecules to OM2 and OM3. Furthermore, the 
MOR:CI2:MOR complex would also have reduced binding affinity for OL and OD, accounting for the de-repression 
of the PL promoter under anti-immune conditions. Model I was our model of choice until we started to interpret 
all data according to the model and tried to find alternative models that could fit the data.
conclusion
We have presented two models for establishment of the anti-immune repression of the PR promoter in TP901-1 
and related bacteriophages against bacteria of Lactococcus, Streptococcus, Enterococcus, and Staphylococcus spe-
cies. The two models differ in the mechanism behind the anti-immune repression of the PR promoter, which leads 
to the lytic cycle of the intact bacteriophage. A number of experiments point at the importance of the postulated 
OM sites that form the basis for both models, and no experiments are in direct contradiction with any of the mod-
els or directly point at one over the others. We will therefore conclude that none of our working models explaining 
TP901-1 decision switching have been falsified, and further detailed structural and functional characterization of 
the CI:MOR complex will be needed to conclude which of the models offer the best description.
Methods
Bacterial strains, transformation and growth conditions. The bacterial strains used in this work 
are listed in Table S1 in supplementary materials. MG1363 was propagated at 30 °C in GM17 media (M17 broth 
from Oxid Limited supplemented with 0.5% glucose)29. Erythromycin (erm) or chlorampenicol (cam) at 5 μg/
ml, was added to the media when appropriate. L. lactis strains were transformed by electroporation as previously 
described3. Screening on 5-bromo-4-choloro-3-indolyl-β-D-galactopyranoside (X-gal) plates were performed at 
a concentration of 90 to 150 μg/ml. Escherichia coli strains was grown at 37 °C with agitation in lysogenization 
broth (LB) media30. Bacto Agar was used at 1.5% (wt/vol) in solid media. 100 μg/ml ampicillin and 8 μg/ml tetra-
cycline was added to the media when appropriate. Electrocompetent E. coli was obtained by growth in LB media 
to OD450 0.8 followed by several washes in 10% glycerol. The cells were stored at –80 °C until electroporation 
(200 Ohm, 25 μFD, 2.0 kV).
DNA techniques. Primers were supplied by TAG Copenhagen A/S Denmark or DNA Technology A/S 
Denmark. The GFXTM PCR DNA and Gel Band Purification Kit were supplied by GE Healthcare Denmark. T4 
DNA ligase, restriction enzymes and buffer systems were supplied by Fermentas GmbH Germanys and used as 
recommend by the supplier. Plasmid DNA from E. coli was isolated using the Qiagen Plasmid kit as described the 
manufacturer (Qiagen). DNA sequencing was performed by Eurofins MWG Operon, Germany, or Macrogen, 
Korea.
Construction of plasmids. The plasmids used in this study are listed in Table S2 in supplementery mate-
rials. Unless otherwise noted, Inserts were amplified by PCR from purified TP901-1 or pMAP50 DNA using 
the primers and vectors indicated in the description. Nucleotide sequence of primers are found in Table S3. All 
constructs were verified by sequencing (Macrogen).
Localized random mutagenesis of OM sites. The relevant fragments were amplified by PCR using the 
degenerate primers indicated in Table S3) and digested with HindIII and PstI. Digested PCR fragments were 
inserted into HindIII and PstI digested pLB85. The correct nucleotide sequence of the resulting fusion plasmids 
pJT2 to pJT13 and pMK1216 to pMK1217 were verified before insertion of the plasmids into the chromosomes of 
JT2 and LB504. Insertion into strain JT2 required co-transformation with plasmid pLB65 encoding the TP901-1 
integrase.
Site directed mutagenesis of the mor gene. Site-specific mutants were introduced in the mor gene 
using the QuickChange Site-Directed Mutagenesis Kit from Stratagene. The reactions were carried out as 
described by the manufacturer. Plasmid pAB223 was used as DNA template and plasmid pMAP109 containing 
alanine codons in postion 36 and 39 in mor was constructed using primers MOR36A39A.for and MOR36A39A.
rev. The construct was verified by sequencing.
Protein purification and pull down experiment using unspecific DNA binding. Partial purification 
of wild type CI protein took advantage of the salt dependent unspecific DNA binding properties of the repressor. 
For over-expression of CI we used E. coli strain AJ159, containing cI in the expression vector pUHE23-2. AJ159 
was grown in LB broth (750 ml) containing 100 μg/ml ampicillin and 8 μg/ml tetracycline at 37 °C with agitation 
to an optical density of 0.6–0.7, induced with isopropyl-1-thio-β-D-galactopyranoside to a final concentration of 
1 mM, and grown for further 2–3 hours. Cells were harvested by centrifugation, washed with buffer A (see below), 
and the cell pellet was stored at −20 °C until used.
E. coli strains expressing wild type MOR (AJ172) or MOR[K36A D39A] mutant (MP1047) from the mor genes 
inserted in the expression vector pUHE23–2 were grown in LB broth (750 ml) containing 100 μg/ml ampicillin 
and 8 μg/ml tetracycline at 37 °C with agitation to an optical density of 0.6–0.7. After this, the culture was induced 
with isopropyl-1-thio-β-D-galactopyranoside to a final concentration of 1 mM, and grown for further 2–3 hours. 
Cells were harvested by centrifugation, washed with buffer A (see below), and the cell pellet was stored at −20 °C 
until used.
The cell pellet was resuspended in 10 ml of buffer A (20 mM Tris/HCl pH 8, 1 mM EDTA, 5 mM MgCl2, 0.1 M 
NaCl) and sonicated on ice. Cell debris and CI protein was sedimented by centrifugation in a Sorvall SS34 rotor 
at 13.000 rpm for 30 minutes. The pellet was resuspended in buffer B, a high salt buffer, (20 mM Tris/HCl pH 8, 
1 mM EDTA, 5 mM MgCl2, 1 M NaCl) and centrifuged using a Sorvall SS34 rotor at 13.000 rpm for 30 minutes.
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Pull down experiments used extracts of MOR from AJ172 or of MOR[K36A D39A] from MP1047, which 
were either subjected directly to trials of purification by unspecific DNA binding, or by mixing of the extracts 
with extracts from AJ172 cells prior to purification by unspecific DNA binding.
Expression, purification and detection of complex-formation by gel filtration of tagged CI and 
MOR derivatives for detection of CI:MOR interaction by gel filtration. E.coli strain BL21(dea) was 
transformed with either pGEX4-2 containing GST-MOR (1–72) or pET30a(+) containing CI-NTD (1–80) + 
linker (81–89). Pre cultures in 10 mL LB medium were used to inoculate 1 L M9 medium containing Glucose 
and NH4Cl for GST-MOR and 1 L LB medium expression cultures for CI-NTD89. At OD600 = 0.6 expression 
were started by adding 0.2 mM or 1 mM IPTG as final concentration for GST-MOR and CI-NTD89, respectively. 
After 20 hours cells were harvested, sonicated and supernatant was collected. The protein of interest was immo-
bilised by loading supernatant onto a GST-Trap equilibrated with PBS pH 7.4 (GE HealthCare) (GST-MOR) or 
His-Trap eqillibrated with 20 mM Tris, 100 mM NaCl pH 7.4 buffer (GE HealthCare) (CI-NTD89). Liberation 
of MOR from the GST linker took advantage of a thrombin cleavage site between GST and MOR. After washing 
the GST-Trap column with PBS, cleavage was performed by injecting 1 mL PBS with 50 unit of Thrombin. After 
16 hours cleavage at room temperature, cleaved MOR were eluted with PBS and purified further by size exclusion 
chromatography (SEC) with 20 mM Tris, 100 mM NaCl pH 7.4 as eluent. CI proteins were eluted with 20 mM 
Tris, 100 mM NaCl, 250 mM Imidazole, pH 7.4, and further purified by SEC with same eluent as MOR.
A Superdex 75 Prep Grad column was equilibrated with 20 mM Tris, 100 mM NaCl, pH 7.4, and gel filtration 
was used to quantify the native size of purified proteins: MOR, NTD89 and MOR:NTD89 mixed in 1:4 ratio.
For calibration of the column 0.25 mg Thyroglobulin (725 kDa), Ferritin (391 kDa), Catalase (202 kDa), 
Aldolase (171 kDa), Albumin (63.5 kDa) or Ribonuclease A (15.6 kDa) (Amersham Biosciences) was used. The 
calibration proteins were run in duplex. Protein elution from the column was monitored at 280 nm.
Chemical cross-linking of complexes containing purified CI and MOR. Chemical cross-linking 
experiments with CI and MOR was performed with pooled fractions from Superdex gel filtration containing 450 
μM and 75 μM CI and MOR, respectively.
CI and/or MOR protein was added at final concentrations of CI at approximately 20 μM, and MOR at 4 μM 
or 20 μM in high stringency binding buffer (20 mM HEPES pH 7.5 200 mM NaCl). At time zero glutaraldehyde 
was added to the protein sample to a final concentration of 0.05% followed by incubation at room temperature. 
Samples were removed after 2, 5, 10, 30 or 60 minutes and prepared for analysis by SDS-PAGE. The molecular 
weight of the protein bands was calculated using a low range molecular weight marker (LMW) and a high range 
molecular weight marker (HMW) from Biorad.
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